
## Kristina Lindemann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3430601/publications.pdf Version: 2024-02-01



KDISTINA LINDEMANN

#	Article	IF	CITATIONS
1	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer, 2005, 113, 678-682.	5.1	227
2	Long-Term Outcomes After Pelvic Radiation for Early-Stage Endometrial Cancer. Journal of Clinical Oncology, 2013, 31, 3951-3956.	1.6	86
3	Serum lipids and endometrial cancer risk: Results from the HUNTâ€II study. International Journal of Cancer, 2009, 124, 2938-2941.	5.1	51
4	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. Annals of Surgical Oncology, 2017, 24, 2720-2726.	1.5	44
5	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. The Cochrane Library, 2019, 2019, 2019, CD012160.	2.8	43
6	Endometrial cancer incidence trends in Norway during 1953–2007 and predictions for 2008–2027. International Journal of Cancer, 2010, 127, 2661-2668.	5.1	42
7	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. Cancers, 2021, 13, 5848.	3.7	40
8	Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer, 2017, 116, 455-463.	6.4	33
9	Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed. International Journal of Gynecological Cancer, 2017, 27, 1274-1282.	2.5	32
10	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology, 2018, 150, 239-246.	1.4	32
11	Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer, 2014, 14, 68.	2.6	30
12	The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. Neuro-Oncology, 2016, 19, now272.	1.2	29
13	Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study. Acta Oncológica, 2017, 56, 1302-1309.	1.8	26
14	L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. BMC Cancer, 2016, 16, 596.	2.6	25
15	Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?. Oncologist, 2005, 10, 480-492.	3.7	19
16	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecologic Oncology, 2016, 142, 458-464.	1.4	17
17	Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey. Gynecologic Oncology, 2015, 139, 476-480.	1.4	16
18	Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2022, 101, 313-322.	2.8	15

#	Article	IF	CITATIONS
19	Enhanced Recovery After Surgery for Suspected Ovarian Malignancy. International Journal of Gynecological Cancer, 2017, 27, 1046-1050.	2.5	11
20	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). International Journal of Gynecological Cancer, 2020, 30, 1997-2001.	2.5	11
21	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American Journal of Obstetrics and Gynecology, 2021, 225, 407.e1-407.e16.	1.3	11
22	Selfâ€reported cognitive impairment in cervical cancer survivors: A crossâ€sectional study. Psycho-Oncology, 2022, 31, 298-305.	2.3	10
23	Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO—a focus on surgical aspects. International Journal of Gynecological Cancer, 2019, 29, 181-187.	2.5	9
24	Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only. International Journal of Gynecological Cancer, 2018, 28, 1789-1795.	2.5	7
25	Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer. Cancers, 2021, 13, 1367.	3.7	7
26	The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. Acta Oncológica, 2021, 60, 434-443.	1.8	7
27	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis Journal of Clinical Oncology, 2020, 38, 6057-6057.	1.6	7
28	Realâ€life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study ( <scp>RESPONSE</scp> trial). Cancer, 2022, 128, 3080-3089.	4.1	7
29	Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking. BMJ Open, 2021, 11, e050930.	1.9	6
30	Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study. International Journal of Gynecological Cancer, 2022, 32, 181-188.	2.5	6
31	Comparison of the Idyllaâ,, CMSI assay with the Promegaâ,, CMSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1031-1039.	2.8	6
32	Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study). European Journal of Epidemiology, 2016, 31, 95-98.	5.7	5
33	Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up Journal of Clinical Oncology, 2012, 30, 5008-5008.	1.6	5
34	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). Cancer Chemotherapy and Pharmacology, 2019, 83, 97-105.	2.3	3
35	Preferences for follow up in longâ€ŧerm survivors after cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 1253-1259.	2.8	3
36	Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. International Journal of Gynecological Cancer, 2020, 30, 1444-1449.	2.5	3

Kristina Lindemann

#	Article	IF	CITATIONS
37	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC) Journal of Clinical Oncology, 2019, 37, TPS5601-TPS5601.	1.6	3
38	Ageâ€related differences in selfâ€report and objective measures of cognitive function in older patients prior to chemotherapy. Nursing Open, 2022, 9, 1040-1051.	2.4	3
39	A Call for New Communication Channels for Gynecological Oncology Trainees. International Journal of Gynecological Cancer, 2017, 27, 620-626.	2.5	2
40	Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002233.	1.6	2
41	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. The Cochrane Library, 2016, , .	2.8	1
42	Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study. International Journal of Gynecological Cancer, 2021, 31, 1106-1115.	2.5	1
43	Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology, 2021, 39, 5560-5560.	1.6	1
44	Association of patient-reported outcomes and ovarian cancer recurrence. International Journal of Gynecological Cancer, 2021, 31, 1248-1259.	2.5	1
45	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome Journal of Clinical Oncology, 2016, 34, 5553-5553.	1.6	1
46	A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer. Scientific World Journal, The, 2008, 8, 905-908.	2.1	0
47	Prediagnostic diabetes, body mass index, and survival of endometrial cancer: A prospective study Journal of Clinical Oncology, 2014, 32, 5601-5601.	1.6	0
48	End of life care in gynaecological cancer patients: A population-based study of cancer deaths from the Swedish Register of Palliative Care Journal of Clinical Oncology, 2018, 36, 10028-10028.	1.6	0
49	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC) Journal of Clinical Oncology, 2022, 40, TPS5611-TPS5611.	1.6	0